Best Oncology Companies in Barcelona, Spain
The 33 best Oncology companies in Barcelona, Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: STAT Diagnostica.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Barcelona
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | STAT Diagnostica Provider of a diagnostic platform for molecular diagnostics and immunoassays | $54M | 120 mo ago | — | Jordi Carrera Co-Founder & Managing Director | — | 113 patents Microfluidic cartridges for nucleic acid purification and biochemical assay automation | — |
| 2 | Ona Therapeutics Provider of therapeutics solution for metastatic cancer | $35M | 12 mo ago | 25 | Valerie Vanhooren Co-Founder & CEO | WordPressBugHerdMySQL+19 | 30 patents FGFR4 and CD36 targeted therapeutics for oncology, including antibodies and small molecules | — |
| 3 | SOM Biotech Developer of platform for screening compounds to treat rare diseases | $29M | 35 mo ago | 15 | Raul Insa Founder & CEO | — | 117 patents Novel small-molecule therapeutics for dystrophinopathies, movement disorders, PKU, and sustained-release formulations | — |
| 4 | ORYZON Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology… | $25M | 18 mo ago | 43 | Carlos Buesa CEO | DrupalApple iCloud MailMicrosoft 365+10 | — | — |
| 5 | Peptomyc Cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment | $23M | 6 mo ago | 18 | Marie-Eve Beaulieu Co-Founder | WordPressMySQLPHP+16 | 60 patents Peptide therapeutics for cancer and autoimmune diseases, plus related diagnostic assays | — |
| 6 | AbilityPharma Developer of drugs for the treatment of cancer diseases | $15M | 31 mo ago | 19 | Jordi Espadaler Co-Founder | Google MapsApache HTTP Serverlit-html+7 | — | — |
| 7 | Nuage Therapeutics Developer of drugs designed for intrinsically disordered targets | $13M | 40 mo ago | 15 | Judit Folgueira Co-Founder & CEO | WordPressMySQLPHP+21 | — | — |
| 8 | Mimark Developer of diagnostic solutions for treating patients with gynecological problems | $7M | 35 mo ago | 2 | Antonio Moreno Co-Founder & CMO | WordPressMySQLPHP+15 | — | — |
| 9 | Onechain Immunotherapeutics Developer of immunotherapies against hematological malignancies | $7M | 32 mo ago | 10 | Pablo Menendez Founder | RubyTrixYouTube+7 | 28 patents Patents concentrated in chemistry & materials | — |
| 10 | Inbiomotion Developer of biomarkers to predict bone metastasis in cancer patients | $5M | 69 mo ago | 10 | — | — | 80 patents Patents concentrated in computing, sensing & instrumentation | — |
| 11 | Gyala Therapeutics Developer of cell therapies for the treatment of hematological malignancies | $4M | 8 mo ago | 5 | — | — | 9 patents CD84-targeted antibody and CAR immunotherapy for cancer and immune modulation | — |
| 12 | Leukos Biotech Developer of drugs targeting leukemic stem cells | $4M | 67 mo ago | 4 | — | — | 55 patents Patents concentrated in health & consumer products | — |
| 13 | Gate2Brain Developer of platform for the delivery of therapeutics across biological barriers | $3M | 39 mo ago | 10 | Esther Riambau Co-Founder | — | 14 patents Peptide-based water‑soluble delivery systems for anticancer drugs and BBB‑crossing antibody shuttles | — |
| 14 | Aptadel Therapeutics Developer of RNA-based therapeutics to treat cancer | $3M | 7 mo ago | 7 | Oscar Tirado Co-Founder | — | 3 patents Aptamer therapeutics targeting EPHA2 receptor for cancer treatment | — |
| 15 | Lykera biomed Monoclonal antibodies (MAbs) as therapy for solid tumors | $2M | 124 mo ago | 1 | Juan Ruiz CEO | — | 55 patents Antibody therapeutics targeting S100 proteins for cancer and fibrotic disease diagnosis and treatment | — |
| 16 | Transbiomed Provider of genomics and proteomics based molecular diagnostics solutions | $2M | 188 mo ago | — | Andreas Doll Co-Founder | — | — | — |
| 17 | Oniria Therapeutics Developer of therapeutics for cancer treatment | $1M | 41 mo ago | 7 | Josep Tabernero Co-Founder | — | — | — |
| 18 | Nanobots Therapeutics Developer of therapeutics for the treatment of cancer | $509K | 23 mo ago | 6 | Andres Fernandez Co-Founder | Froala EditorVimeoBootstrap+14 | — | — |
| 19 | Pangaea Biotech Provider of drug development and molecular diagnostics services on cancer treatment | $298K | 106 mo ago | 55 | — | WordPressMySQLPHP+22 | 104 patents Molecular diagnostics, nucleic acid isolation, luminescent biomarker assays, and oncology therapeutics | — |
| 20 | YSOTOPE Developer of radiotracers to monitor CAR-T cells inside the patient’s body | $160K | 40 mo ago | 5 | Carlos Gavilan Co-Founder & CEO | — | — | — |
| 21 | MiWEndo Solutions Developer of electromagnetic endoscopy for colorectal cancer detection | $121K | 69 mo ago | 19 | Gloria Esparrach Co-Founder | WordPressMySQLPHP+22 | 2 patents Endoscopic accessory devices for medical imaging and procedures | — |
| 22 | Moirai Biodesign Developer of RNA-based therapeutics and diagnostics for cancer | $115K | 88 mo ago | 6 | Ivan Dotu Co-founder and CTO | — | 11 patents Amplified RNA aptamer-based nucleic acid detection for disease diagnostics. | — |
Top 12 Oncology companies in Barcelona
#1
Series C · Barcelona, Catalonia · founded 2014 · 18 employees$22.6Mraised▾
Peptomyc, a spin-off of the Vall d’Hebron Institute of Oncology (VHIO) is focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. Its lead peptide Omomyc-CPP is in the preclinical stage.
- Apr 2026Series C$5.8M
- Feb 2026Series B—
- Oct 2023Grant (prize money)$2.6M
- Oct 2023Series B$2.6M
#2
Series A · Barcelona, Catalonia · founded 2019 · 25 employees$35.5Mraised▾
Ona Therapeutics provides therapeutics solution for metastatic cancer. It is a spin-off of ICREA and IRB and involved in developing biologics targeting the metastatic-initiating cells and lipid metabolism for the treatment of cancer.
- Oct 2025Series A$11.6M
- Dec 2020Grant (prize money)—
- Jun 2020Series A$33.8M
- May 2019Seed$1.7M
#3
Seed · Barcelona, Catalonia · founded 2020 · 7 employees$2.8Mraised▾
Developer of RNA-based therapeutics to treat cancer. The company's technology is based on RNA-Aptamers to deliver different therapeutic agents to treat a wide variety of cancers. The company's lead candidate drug is ADEL-101 for Ewing Sarcoma, a rare variety of bone cancer in children and young adults.
- Mar 2026Seed$2.3M
- 2025Seed$498.5K
#4
Early Stage · Barcelona, Catalonia · founded 2020 · 5 employees$4.4Mraised▾
Developer of cell therapies for the treatment of hematological malignancies. The company is developing CAR T cell products against a novel target overexpressed in several hematological malignancies. The product line inlcudes ARI-0001 and ARI-0002 for chronic lymphocytic leukemia (CLL), Burkitt’s lymphoma, acute myeloid leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL).
- Feb 2026Grant (prize money)$4.4M
#5
Public · Barcelona, Catalonia · founded 2000 · 43 employees$24.9Mraised▾
Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology platforms. It uses a proprietary epigenetic platform to identify drug targets for cancer and neurodegenerative diseases. Its lead candidate targets lysine-specific demethylase - 1 (LSD-1) for Alzheimer's, Parkinson's, Huntington's, and certain other rare diseases.
- Apr 2025Post IPO$34.1M
- Sep 2021Grant (prize money)$1M
- Jul 2019Post IPO$22.3M
- Mar 2017Post IPO$19.5M
#6
Series B · Barcelona, Catalonia · founded 2009 · 15 employees$28.5Mraised▾
SOM Biotech is developing therapies for rare diseases. The company has developed a proprietary ligand-based in-silico platform for virtual compound screening. The company has developed a drug pipeline that includes SOM0226 for the treatment of TTR amyloidosis (phase II) and SOM3355 for the treatment of Huntington's disease (phase II). The other products in the pipeline include compounds for the treatments for cystic fibrosis, glioblastoma, and Alzheimer's disease.
- Dec 2023Series B$18.5M
- Mar 2019Series A$7.9M
- Jan 2017Seed$2.1M
#7
Series B · Barcelona, Catalonia · founded 2009 · 19 employees$14.5Mraised▾
Ability Pharma is a developer of drugs for the treatment of cancer diseases. It has developed the ABTL0812 product that indicated for solid tumors started phase I/Ib trials, first in humans in Feb.2014. They have 4 other molecules in preclinical and discovery validation stages such as ABTL0815, ABTL0814, and others.
- Mar 2024Series B$7.7M
- Jul 2020Grant (prize money)$2.6M
- Sep 2019Series A$3.9M
- Feb 2013Grant (prize money)$1.6M
#8
Seed · Barcelona, Catalonia · founded 2020 · 10 employees$7.3Mraised▾
Developer of immunotherapies against hematological malignancies. The company develops immunotherapies against hematological neoplasms using CAR-T candidates against different antigens. The product pipeline inlcudes OC-1 CART CD1a immunotherapy for refractory relapsed patients, OC-2 CART CD22 Immunotherapy, and OC-3 a T-cell allogeneic platform.
- Feb 2024Grant (prize money)$2.4M
- Jun 2023Seed$7.3M
- Apr 2023Grant (prize money)$1.6M
#9
Seed · Barcelona, Catalonia · founded 2021 · 2 employees$7.5Mraised▾
Developer of diagnostic solutions for treating patients with gynecological problems. The company is involved in the development of biomarkers that acts as an indicator of a particular disease state. It can be introduced into an organism to examine organ function or to evaluate abnormal vaginal bleeding problems in women. It also helps in the diagnosis of endometrial cancer.
- Nov 2023Seed$4.6M
- Jun 2023Seed$1.1M
- Feb 2021Seed$1.8M
#10
Seed · Barcelona, Catalonia · founded 2021 · 15 employees$13.1Mraised▾
Developer of drugs designed for intrinsically disordered targets. The company develops drug screening assays to target intrinsically disordered proteins that undergo biomolecular condensation and provide treatment of castration-resistant prostate cancer.
- Jun 2023Seed$13.1M
#11
Seed · Barcelona, Catalonia · founded 2023 · 6 employees$509.1Kraised▾
Developer of therapeutics for the treatment of cancer. It offers a lead candidate NBT-101 for bladder cancer, NBT-102 for colorectal cancer, and others. It offers a proprietary MotionTx technology platform to develop therapeutic candidates that cano cross biological barriers and accumulate in target cells.
- Dec 2024Seed$1.1M
- Sep 2023Seed$509.1K
#12
Series C · Barcelona, Catalonia · founded 2010$53.7Mraised▾
Provider of a diagnostic platform for molecular diagnostics and immunoassays. The proprietary DiagCore comprises an Analyzer that runs on consumable DiagCore cartridges. The STAT-Molecular cartridge automates sample homogenization, cell disruption, nucleic acid purification and delivers up to 50-plex target detection employing qPCR. This test cartridge is designed to automate molecular assays in the fields of infectious diseases, oncology, coagulation, prenatal, inherited diseases, or companion diagnostics. It offers test cartridges designed to automate immunoassays for critical care markers such as Procalcitonin (Sepsis), Troponin (AMI), Ngal (AKI), C-reactive protein (Inflammation), hCG (pregnancy), among others.
- Oct 2016Series C—
- Apr 2016Series C$28.5M
- May 2013Series B$22.3M
- 2011Series A$2.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in Barcelona is moving
A read on the academic research around Oncology in Barcelona — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 66 papers.
- Hospital Clínic de Barcelona21
- Universitat Autònoma de Barcelona17
- Universitat de Barcelona16
- Institut d\'Investigacions Biomèdiques de Barcelona5
- Hospital Sant Joan de Déu Barcelona4
- Tumor microenvironment1→6
- Tumor microenvironment19
- Cancer research13
- Cancer10
- Immune system10
- Immunotherapy9
- Immunotherapy5
- Immune system5
- Tumor microenvironment4
- Cancer3
- Cancer research2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.